Immuneering Corporation (IMRX)
NASDAQ · Healthcare
Immuneering Corporation Operating Income 2020–2023
Immuneering Corporation annual/quarterly operating income history and growth rate from 2020 to 2023. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Immuneering Corporation operating income for the quarter ending September 30, 2023 was -13.9 M, a 5.60% increase year-over-year.
- Immuneering Corporation operating income for the twelve months ending September 30, 2023 was -55.3 M, a 34.53% increase year-over-year.
- Immuneering Corporation annual operating income for 2023 was -58.4 M, a 12.89% increase from 2022.
- Immuneering Corporation annual operating income for 2022 was -51.7 M, a 52.70% increase from 2021.
- Immuneering Corporation annual operating income for 2021 was -33.9 M, a 98.37% increase from 2020.
- Immuneering Corporation annual operating income for 2020 was -17.1 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Immuneering Corporation Operating Income — FAQ
Immuneering Corporation (IMRX) operating income over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
What is Immuneering Corporation's operating income?
Immuneering Corporation (IMRX) reported operating income of -$58M for fiscal 2023.
Where can I see IMRX's operating income history?
The chart and table above show Immuneering Corporation's operating income by year and by quarter, including the growth rate.